

# **Injecto A/S**

Strandvejen 60, 5., 2900 Hellerup

CVR no. 38 72 98 88

## Annual report 2022/23

Approved at the Company's annual general meeting on 15 January 2024

Chair of the meeting:

.....  
Torben Helmer Knudsen

## Contents

Statement by the Board of Directors and the Executive Board	2
Independent auditor's report	3
Management's review	5
Financial statements 1 September 2022 - 31 August 2023	8
Income statement	8
Balance sheet	9
Statement of changes in equity	11
Notes to the financial statements	12

## Statement by the Board of Directors and the Executive Board

Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Injecto A/S for the financial year 1 September 2022 - 31 August 2023.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 August 2023 and of the results of the Company's operations for the financial year 1 September 2022 - 31 August 2023.

Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the annual general meeting.

Hellerup, 15 January 2024  
Executive Board:

.....  
Torben Helmer Knudsen  
Chief Executive Officer

Board of Directors:

.....  
John Holger Adamsen  
Chairman

.....  
Torben Helmer Knudsen

.....  
Thomas Sonne-Schmidt

## Independent auditor's report

To the shareholder of Injecto A/S

### Opinion

We have audited the financial statements of Injecto A/S for the financial year 1 September 2022 - 31 August 2023, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 August 2023 and of the results of the Company's operations for the financial year 1 September 2022 - 31 August 2023 in accordance with the Danish Financial Statements Act.

### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.

### Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- ▶ Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- ▶ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- ▶ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.

## Independent auditor's report

- ▶ Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- ▶ Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

### Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 15 January 2024  
EY Godkendt Revisionspartnerselskab  
CVR no. 30 70 02 28

Jesper Jørn Pedersen  
State Authorised Public Accountant  
mne21326

## Management's review

### Company details

Name	Injecto A/S
Address, Postal code, City	Strandvejen 60, 5., 2900 Hellerup
CVR no.	38 72 98 88
Established	19 June 2017
Registered office	Gentofte
Financial year	1 September 2022 - 31 August 2023
Board of Directors	John Holger Adamsen, Chairman Torben Helmer Knudsen Thomas Sonne-Schmidt
Executive Board	Torben Helmer Knudsen, Chief Executive Officer
Auditors	EY Godkendt Revisionspartnerselskab Dirch Passers Allé 36, P.O. Box 250, 2000 Frederiksberg, Denmark

## Management's review

### Business review

Injecto A/S develops, manufactures, and sells components for pharmaceutical packaging mainly for pre-fillable injection systems ("PFS") on the basis of the licenses on patent rights from the Injecto Group A/S.

Injecto A/S' main focus is the series of lubrigone plunger stoppers for PFS in ISO measurements but also in individual measurements based on specific company wishes, which plunger stoppers ensure a lubrication free PFS, which is in demand from pharma companies specialised in biologics and in medical preparations for sensitive organs such as eyes, ears, central nervous system, brain etc.

The company has two established production lines at SP Medical ([www.sp-medical.com](http://www.sp-medical.com)) as its OEM manufacturer on lubrigone3 plunger stoppers for PFS in respectively a volume of 0.5 ml and 1.0 ml (long) and has increased its contacts with the world's leading pharmaceutical companies and some of the leading manufacturers in PFS.

Injecto A/S' investment in a third production line for lubrigone stoppers for 1-3 ml PFS in ISO measurements in addition to the two aforementioned production lines, which production is being implemented and validated, ensures that Injecto A/S' can supply samples in all three basic ISO measurements of PFS for tests from an industrial production to pharma customers and at the same time offer the pharma customers industrial supplies without bottlenecks.

Due to Injecto A/S' strong competitive edge related to the flexibility and efficient production based on the lubrigone concept Injecto A/S can offer the pharma companies and companies in other business area like diagnostics a strong value proposition with respect to the development of the best individual solution and with a much shorter timeline related to a production in industrial scale.

It should be noted that Injecto A/S' products are supplied to primary packaging for pharma, which supplies are defined by extensive testing and hence longer lead times. The longer lead times are matched by long-term lucrative contracts.

By the three industrial production lines Injecto A/S has furthermore verified production times and production costs and has built up a reserve that over the coming years will ensure a substantial revenue and a significant profit without further investments. Injecto A/S has also verified that a further scale-up of Injecto Group A/S' current yearly production capacity of a two-digit million figure can be increased to a yearly production capacity in a three-digit million figure within 9-12 months.

Injecto A/S has also been carrying out the co-operation with PATH and its donators and some pharma companies about the easyject syringe, but dependable on the outcome and the resources Injecto A/S and its parent company will consider if the production and sales and marketing of the easyject syringe shall be carried out by another subsidiary under Injecto Group A/S. If this turned out to be the case Injecto A/S will most likely still produce the lubrigone stoppers to be used in the easyject syringe, where the current plan is an initial yearly production of 50 million stoppers for this syringe.

### Financial review

The income statement for 2022/23 shows a loss of DKK 2,627 thousand against a loss of DKK 4,086 thousand last year, and the balance sheet at 31 August 2023 shows equity of DKK 3,382 thousand. The company's financial result with a total loss of DKK 2,627 thousand reflects that the company is in the initialization of its commercial activities.

Injecto A/S aimed at coming into commercial profitable operation before the end of 2023 but has to realise that this will take longer time, which is caused by the significant interest from the high-end biologic market, which market is in an early stage. Injecto A/S believe that a more patient approach, where this part of the market is secured, will give the company a better strategic position and increase the revenues and profit margins over time.

Despite Injecto A/S is still financially supported by its parent company, the company still expects that the developments in its commercial activities will make the company independent of financial support in the future.

In this respect full use of Injecto A/S' established production capacity of the three production lines represents a substantial EBITDA.

## Management's review

### Events after the balance sheet date

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.

Due to the successful preliminary tests of the lubrigone stopper's capability to maintain its functionality as an integrated part of a prefilled injection device with pharma stored at minus 80 degrees Celsius and prior to use exposed to the impact from thawing, the company is in first half of the calendar year entering the negotiation with one of the world's leading global pharma companies about a specific project. A successful outcome of this project will create a substantial awareness and respect of Injecto A/S in the market for biologics and especially in the market for cell & gene technology - in addition to the expected revenue the project will be able to generate from the specific pharma company over the years to come. Since Injecto cannot rely on one single customer Injecto is working on the initialisation of supplementary projects in the high-end market.



## Financial statements 1 September 2022 - 31 August 2023

### Income statement

Note	DKK	2022/23	2021/22
	<b>Gross profit/loss</b>	-1,585,250	-2,931,492
	Amortisation/depreciation and impairment of intangible assets and property, plant and equipment	-475,645	-859,353
	<b>Profit/loss before net financials</b>	-2,060,895	-3,790,845
	Financial income	3,995	0
4	Financial expenses	-569,686	-295,573
	<b>Profit/loss before tax</b>	-2,626,586	-4,086,418
	Tax for the year	0	0
	<b>Profit/loss for the year</b>	-2,626,586	-4,086,418
<b>Recommended appropriation of profit/loss</b>			
	Retained earnings/accumulated loss	-2,626,586	-4,086,418
		-2,626,586	-4,086,418

## Financial statements 1 September 2022 - 31 August 2023

### Balance sheet

Note	DKK	2022/23	2021/22
	<b>ASSETS</b>		
	<b>Fixed assets</b>		
5	<b>Property, plant and equipment</b>		
	Fixtures and fittings, other plant and equipment	220,374	696,019
	Property, plant and equipment under construction	1,842,674	1,065,750
		2,063,048	1,761,769
	<b>Total fixed assets</b>	2,063,048	1,761,769
	<b>Non-fixed assets</b>		
	<b>Receivables</b>		
	Trade receivables	374,165	97,537
	Other receivables	478,586	479,784
		852,751	577,321
	<b>Cash</b>	1,039,353	104,021
	<b>Total non-fixed assets</b>	1,892,104	681,342
	<b>TOTAL ASSETS</b>	3,955,152	2,443,111

## Financial statements 1 September 2022 - 31 August 2023

### Balance sheet

Note	DKK	<u>2022/23</u>	<u>2021/22</u>
	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	Share capital	2,500,000	2,000,000
	Share premium account	0	0
	Retained earnings	881,765	-8,991,649
	<b>Total equity</b>	<u>3,381,765</u>	<u>-6,991,649</u>
	<b>Liabilities other than provisions</b>		
	<b>Current liabilities other than provisions</b>		
	Trade payables	313,240	171,477
	Payables to group enterprises	211,991	9,216,383
	Other payables	48,156	46,900
		<u>573,387</u>	<u>9,434,760</u>
	<b>Total liabilities other than provisions</b>	<u>573,387</u>	<u>9,434,760</u>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<u><u>3,955,152</u></u>	<u><u>2,443,111</u></u>

- 1 Accounting policies
- 2 Going concern uncertainties
- 3 Staff costs
- 6 Contractual obligations and contingencies, etc.
- 7 Security and collateral
- 8 Related parties

## Financial statements 1 September 2022 - 31 August 2023

### Statement of changes in equity

DKK	Share capital	Share premium account	Retained earnings	Total
<b>Equity at 1 September 2022</b>	2,000,000	0	-8,991,649	-6,991,649
Capital increase	500,000	12,500,000	0	13,000,000
Transfer through appropriation of loss	0	0	-2,626,586	-2,626,586
Transferred from share premium account	0	-12,500,000	12,500,000	0
<b>Equity at 31 August 2023</b>	<b>2,500,000</b>	<b>0</b>	<b>881,765</b>	<b>3,381,765</b>

## Financial statements 1 September 2022 - 31 August 2023

### Notes to the financial statements

#### 1 Accounting policies

The annual report of Injecto A/S for 2022/23 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

#### Reporting currency

The financial statements are presented in Danish kroner (DKK).

#### Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rate at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the most recent financial statements is recognised in the income statement as financial income or financial expenses.

#### Income statement

##### Revenue

The Company has chosen IAS 11/IAS 18 as interpretation for revenue recognition.

Income from the rendering of services is recognised as revenue as the services are rendered. Accordingly, revenue corresponds to the market value of the services rendered during the year (percentage-of-completion method).

Revenue is measured at the fair value of the agreed consideration excluding VAT and taxes charged on behalf of third parties. All discounts and rebates granted are recognised in revenue.

##### Gross profit/loss

The items revenue, cost of sales and external expenses have been aggregated into one item in the income statement called gross profit/loss in accordance with section 32 of the Danish Financial Statements Act.

##### Other external expenses

Other external expenses include the year's expenses relating to the Company's core activities, including expenses relating to administration etc.

##### Depreciation

The item comprises depreciation of property, plant and equipment.

The basis of depreciation, which is calculated as cost less any residual value, is depreciated on a straight line basis over the expected useful life. The expected useful lives of the assets are as follows:

Fixtures and fittings, other plant and equipment	3 years
--------------------------------------------------	---------

## Financial statements 1 September 2022 - 31 August 2023

### Notes to the financial statements

#### 1 Accounting policies (continued)

Depreciation is based on the residual value of the asset and is reduced by impairment losses, if any. The depreciation period and the residual value are determined at the acquisition date and are reassessed annually. Where the residual value exceeds the carrying amount of the asset, no further depreciation charges are recognised.

In the case of changes in the depreciation period or the residual value, the effect on the depreciation charges is recognised prospectively as a change in accounting estimates.

#### Financial income and expenses

Financial income and expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest income and expenses as well as allowances and surcharges under the advance-payment-of-tax scheme, etc.

#### Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

The entity is jointly taxed with other group entities. The total Danish income tax charge is allocated between profit/loss-making Danish entities in proportion to their taxable income (full absorption).

Jointly taxed entities entitled to a tax refund are reimbursed by the management company based on the rates applicable to interest allowances, and jointly taxed entities which have paid too little tax pay a surcharge according to the rates applicable to interest surcharges to the management company.

#### Balance sheet

##### Property, plant and equipment

Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.

Gains or losses are calculated as the difference between the selling price less selling costs and the carrying amount at the date of disposal. Gains and losses from the disposal of property, plant and equipment are recognised in the income statement as other operating income or other operating expenses.

##### Impairment of fixed assets

The carrying amount of property, plant and equipment is assessed for impairment on an annual basis.

Impairment tests are conducted on assets or groups of assets when there is evidence of impairment. The carrying amount of impaired assets is reduced to the higher of the net selling price and the value in use (recoverable amount).

The recoverable amount is the higher of the net selling price of an asset and its value in use. The value in use is calculated as the present value of the expected net cash flows from the use of the asset or the group of assets and the expected net cash flows from the disposal of the asset or the group of assets after the end of the useful life.

Previously recognised impairment losses are reversed when the reason for recognition no longer exists.

## Financial statements 1 September 2022 - 31 August 2023

### Notes to the financial statements

#### 1 Accounting policies (continued)

##### Receivables

The Company has chosen IAS 39 as interpretation for impairment write-down of financial receivables.

Receivables are measured at amortised cost.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.

Receivables in respect of which there is no objective evidence of individual impairment are tested for objective evidence of impairment on a portfolio basis. The portfolios are primarily based on the debtors' domicile and credit ratings in line with the Company's risk management policy. The objective evidence applied to portfolios is determined based on historical loss experience.

Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate.

##### Equity

##### *Proposed dividends*

Dividend proposed for the year is recognised as a liability once adopted at the annual general meeting (declaration date). Dividends expected to be distributed for the financial year are presented as a separate item under "Equity".

##### Liabilities

The Company has chosen IAS 39 as interpretation for liabilities.

Financial liabilities are recognised at the date of borrowing at the net proceeds received less transaction costs paid. On subsequent recognition, financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest rate. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan. Financial liabilities also include the capitalised residual lease liability in respect of finance leases.

Other liabilities are measured at net realisable value.

#### 2 Going concern uncertainties

The parent company Injecto Group A/S has provided letter of comfort to Injecto A/S. Injecto Group A/S will unconditionally cover Injecto A/S liquidity needs by capital injection(s) or by subordinated loan(s) for its operation of its business activities until the Company is in profitable operation or has obtained alternative funding for its operation.

The letter of comfort can be terminated with 12 months prior written note to Injecto A/S.

## Financial statements 1 September 2022 - 31 August 2023

### Notes to the financial statements

#### 3 Staff costs

The Company has no employees.

DKK	2022/23	2021/22
<b>4 Financial expenses</b>		
Interest expenses, group entities	569,358	293,093
Other financial expenses	328	2,480
	569,686	295,573

#### 5 Property, plant and equipment

DKK	Fixtures and fittings, other plant and equipment	Property, plant and equipment under construction	Total
Cost at 1 September 2022	1,943,764	1,065,750	3,009,514
Additions	0	776,924	776,924
Disposals	-390,150	0	-390,150
Cost at 31 August 2023	1,553,614	1,842,674	3,396,288
Impairment losses and depreciation at 1 September 2022	1,247,745	0	1,247,745
Depreciation	475,645	0	475,645
Reversal of accumulated depreciation and impairment of assets disposed	-390,150	0	-390,150
Impairment losses and depreciation at 31 August 2023	1,333,240	0	1,333,240
<b>Carrying amount at 31 August 2023</b>	220,374	1,842,674	2,063,048
Depreciated over	3 years		

#### 6 Contractual obligations and contingencies, etc.

##### Other contingent liabilities

The Company is jointly taxed with its parent, Injecto Group A/S, which acts as management company, and is jointly and severally liable with other jointly taxed group entities for payment of income taxes for the income year 2018 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 19 June 2017.

##### Other financial obligations

Other rent liabilities:

DKK	2022/23	2021/22
Rent liabilities	372,600	372,600

#### 7 Security and collateral

The Company has not provided any security or other collateral in assets at 31 August 2023.



## Financial statements 1 September 2022 - 31 August 2023

### Notes to the financial statements

#### 8 Related parties

##### Information about consolidated financial statements

<u>Parent</u>	<u>Domicile</u>	<u>Requisitioning of the parent company's consolidated financial statements</u>
Injecto Group A/S	Strandvejen 60 DK-2900 Hellerup	Injecto Group A/S Strandvejen 60 DK-2900 Hellerup

# PENNEO

Underskrifterne i dette dokument er juridisk bindende. Dokumentet er underskrevet via Penneo™ sikker digital underskrift. Underskrivernes identiteter er blevet registreret, og informationerne er listet herunder.

“Med min underskrift bekræfter jeg indholdet og alle datoer i dette dokument.”

## Torben Helmer Knudsen

### Direktion

På vegne af: Injecto AS

Serienummer: a6f9560f-506b-44a1-9841-28af01faee4d

IP: 94.145.xxx.xxx

2024-01-15 20:14:49 UTC



## Torben Helmer Knudsen

### Dirigent

På vegne af: Injecto AS

Serienummer: a6f9560f-506b-44a1-9841-28af01faee4d

IP: 94.145.xxx.xxx

2024-01-15 20:19:28 UTC



## Torben Helmer Knudsen

### Bestyrelse

På vegne af: Injecto AS

Serienummer: a6f9560f-506b-44a1-9841-28af01faee4d

IP: 94.145.xxx.xxx

2024-01-15 20:24:19 UTC



## Thomas Sonne-Schmidt

### Bestyrelse

På vegne af: Injecto AS

Serienummer: 7a990ebd-04d4-40b6-8a79-1027b7ade3a2

IP: 188.183.xxx.xxx

2024-01-15 20:26:49 UTC



## John Holger Adamsen

### Bestyrelse

På vegne af: Injecto AS

Serienummer: da6beb08-0544-487f-9548-e9403ce4385d

IP: 77.241.xxx.xxx

2024-01-15 22:19:10 UTC



## Jesper Jørn Pedersen

EY Godkendt Revisionspartnerselskab CVR: 30700228

Statsautoriseret revisor

På vegne af: EY Godkendt Revisionspartnerselskab

Serienummer: 56d6c3a0-9f8e-441c-9edb-c29124a844b6

IP: 165.225.xxx.xxx

2024-01-16 07:52:27 UTC



Penneo dokumentnøgle: F7010-1M4EQ-H45J-VM4U7-5U7LN-IA1ZY

Dette dokument er underskrevet digitalt via **Penneo.com**. Signeringsbeviserne i dokumentet er sikret og valideret ved anvendelse af den matematiske hashværdi af det originale dokument. Dokumentet er låst for ændringer og tidsstempelt med et certifikat fra en betroet tredjepart. Alle kryptografiske signeringsbeviser er indlejret i denne PDF, i tilfælde af de skal anvendes til validering i fremtiden.

### Sådan kan du sikre, at dokumentet er originalt

Dette dokument er beskyttet med et Adobe CDS certifikat. Når du åbner dokumentet

i Adobe Reader, kan du se, at dokumentet er certificeret af **Penneo e-signature service <penneo@penneo.com>**. Dette er din garanti for, at indholdet af dokumentet er uændret.

Du har mulighed for at efterprøve de kryptografiske signeringsbeviser indlejret i dokumentet ved at anvende Penneos validator på følgende websted: **https://penneo.com/validator**